Navigation Links
Selexis SA to Partner and Exhibit at BIO 2013

Geneva, Switzerland (PRWEB) April 10, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO International Convention’s One-on-One Partnering Meetings being held April 22 – 25, 2013 at McCormick Place in Chicago, IL.

Selexis has partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Selexis’ SUREtechnology Platform™ offers a range of solutions for expressing genes in CHO cells and other mammalian systems and addresses issues such as over-expression of membrane proteins, secretion bottlenecks with difficult-to express proteins and development of high producing clonal cell lines for therapeutic protein programs. Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines that can be applied to a wide range of areas such as diagnostics, drug discovery, therapeutics and bio-manufacturing.

Representatives will be available to discuss Selexis’ capabilities. Companies or individuals attending BIO 2013 can schedule meetings with Selexis by visiting (registration required):

Selexis Business Forum Partnering Schedule:

  •     Monday, April 22    Business Forum - 08:00 AM – 05:00 PM
  •     Tuesday, April 23    Business Forum - 08:00 AM – 05:00 PM
  •     Wednesday, April 24    Business Forum - 08:00 AM – 05:00 PM
  •     Thursday, April 25    Business Forum - 08:00 AM – 12:00 PM

For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #4158 located in Hall C

Selexis Exhibit Hall Schedule and Partnering:

  •     Monday, April 22    Hall C - 12:00 PM – 05:00 PM
  •     Tuesday, April 23    Hall C - 10:00 AM – 05:00 PM
  •     Wednesday, April 24    Hall C - 10:00 AM – 05:00 PM
  •     Thursday, April 25    Hall C - 10:00 AM – 12:00 PM

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA to Present and Partner at the BIO-Europe Spring
2. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
3. Healthy Vending Snacks Arrive to Philadelphia Rregion’s Most Honored and Respected Teaching Hospital; Thanks to Partnership with Award-Winning Food Services Provider
4. Team Red, White and Blue Enters Partnership with SteamVita to Support Combat Veterans and Families
5. BOMI International and Transwestern Partner to Offer Property and Facility Staff Skill-Enhancing Education Programs
6. Alliance Storage Technologies and Blue Chip Technical Services (Pvt) Ltd. Announce Partnership to Expand the Reach of Professional Data Archiving Solutions
7. ReviMedia Partners with RingRevenue to Deliver a Comprehensive Lead Generation Solution
8. The Signature Group, Inc. Partners with Alert Logic to Deliver Security and Compliance Solutions
9. Audiology Associates & Hearing Aids Today—Provider of Hearing Aids in Nashville TN—Released New Article for Coping Strategies for Partners
10. Doctors Spouses, Partners Say Theyre Satisfied
11. Brett A. Carter, Partner of Benson, Bertoldo, Baker & Carter, Received an AV Rating by Martindale-Hubbell
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
(Date:11/25/2015)... ... 2015 , ... Many people know of the common symptoms of low thyroid ... skin. But many people who find their cholesterol levels and weight are creeping up ... especially if they don’t have any of the other symptoms. , Thyroid hormone plays ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... Tuberous Sclerosis Complex (TSC), as well as raising public awareness of the disorder ... need it—presented a third donation of $35,000 to bolster progress at the Tuberous ...
(Date:11/25/2015)... ... ... Since its launch in 2012, the Regenestem brand ( ... to patients with chronic degenerative medical conditions. Now, the U.S. Patent and Trademark ... Organizations are required to hold a registered trademark in order to make licensing ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to ... of the Create Real Impact awards. California Casualty is proud to support ... tide of distracted and reckless driving, the number one killer of young drivers. ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 - Will ... Medical Education (CME) --> - Will ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) ... products and services, will feature latest diagnostic imaging textbooks and decision ...
(Date:11/25/2015)... 25, 2015 Research and Markets ( ... Market - Global Forecast to 2020" report to ... accounting for 37.21% of the total market share in ... region is projected to growth at the highest ... attributed primarily to the fast growing water, industrial gas ...
(Date:11/25/2015)... --> --> ... für das Patent über eine neue Hepatitis-B-Behandlung, welches sie ... an Enyo Pharma vergeben haben. Im Rahmen ... und von Edelris gemeinsam mit seinen Partnern Inserm und ... HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die ...
Breaking Medicine Technology: